Miromatrix Medical Inc.
MIRO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MIRO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2023.
Tracking 3 pipeline candidates · 1 clinical trial for Miromatrix Medical Inc..
Run Miromatrix Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Miromatrix Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
6.6 months
D/E 0.51
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Miromatrix Medical Inc.'s lead drug candidate?
Miromatrix Medical Inc.'s most advanced tracked candidate is mirokidney (Preclinical) for End-stage renal disease (ESRD).
Who is the CEO of Miromatrix Medical Inc.?
Flying Cloud Drive is the chief executive officer of Miromatrix Medical Inc. (MIRO).
What therapeutic areas does Miromatrix Medical Inc. focus on?
Miromatrix Medical Inc. develops therapies across Oncology, Neurology, Immunology, Infectious Disease, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.